Simulations Plus, Inc. Reports Unaudited Consolidated Financial Results for First Quarter Ended November 30, 2016
January 09, 2017 at 09:01 pm
Share
Simulations Plus, Inc. reported unaudited consolidated financial results for first quarter ended November 30, 2016. For the quarter, the company reported net revenues were $5,417,934 compared to $4,838,620 for the same period a year ago. Income from operations was $1,928,096 compared to $1,727,533 for the same period a year ago. Income from operations before provision for income taxes was $1,957,480 compared to $1,717,105 for the same period a year ago. Net Income was $1,361,565 compared to $1,106,473 for the same period a year ago. Diluted earnings per share were $0.08 compared to 0.06 for the same period a year ago.
Simulations Plus, Inc. is a provider of modeling and simulation software and services for pharmaceutical drug discovery and development, including the prediction of properties of molecules utilizing both artificial intelligence and machine-based technology. Its segments include software and services. It offers 12 software products for pharmaceutical research and development: GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, MonolixSuite, ADMET Predictor and MedChem Designer. Its services include population pharmacokinetic and pharmacodynamic, quantitative systems pharmacology/quantitative systems toxicology, and physiologically based pharmacokinetic. The Company provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions supporting product approval. The Company also provides tech-enabled training and compliance solutions for clinical trial investigators and site staff.
SIMULATIONS PLUS, INC. 
